Navigation Links
Optimer to Provide DIFICID™ Launch Update at Morgan Stanley Global Healthcare Conference
Date:9/12/2011

SAN DIEGO, Sept. 12, 2011 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) announced that the Company will provide an update on the DIFICID™ (fidaxomicin) tablets launch at the Morgan Stanley Global Healthcare Conference taking place in New York City. Pedro Lichtinger, Optimer's President and CEO, will comment on the DIFICID launch tomorrow, September 13, during a webcasted fireside chat at 8:00 AM ET. DIFICID was approved by the U.S. Food and Drug Administration in May of 2011 for the treatment of Clostridium difficile-associated diarrhea (CDAD) in adults 18 years of age and older. CDAD is a significant medical problem in hospitals and long-term care facilities, and DIFICID is the first antibacterial drug approved for the treatment of CDAD in 25 years.

(Logo: http://photos.prnewswire.com/prnh/20090413/LA97352LOGO)

"We believe the Optimer strategy is proving highly impactful, with DIFICID sales exceeding published analyst expectations in the initial stages of the launch. While early in the launch, we view it as a major success to date. We are committed to maintaining this momentum as the launch matures," said Pedro Lichtinger, president and CEO of Optimer Pharmaceuticals. "The growing evidence of the value of DIFICID to patients, hospitals and payers  is being well received by practitioners and other stakeholders. Supported by DIFICID's clinical strength and value proposition, we believe the combined Optimer/Cubist field presence is having a material impact on accelerating prescriptions and formulary adoption."

There are several key components comprising the DIFICID launch effort and Optimer plans to review progress to date for each of those components.

1. DIFICID Sales

For the period of July 19, the date of DIFICID's first sales, through September 2 , Optimer estimates DIFICID gross sales of $
'/>"/>

SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Optimer Pharmaceuticals DIFICID Featured in 11 Presentations at 51st ICAAC
2. Optimer Pharmaceuticals to Present at September 2011 Investor Conferences
3. Optimer Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
4. Clinical Infectious Diseases Publishes Subgroup Analysis Showing Optimers DIFICID™ (fidaxomicin) Tablets Exhibited Higher Clinical Cure and Global Cure Rates Than Vancomycin in Patients with Clostridium difficile-Associated Diarrhea (CDAD) Receivin
5. Optimer Pharmaceuticals Reports Second Quarter 2011 Financial Results
6. Optimer Launches DIFICID™ (fidaxomicin) Tablets for Treatment of Clostridium Difficile-Associated Diarrhea (CDAD) in Patients 18 Years of Age and Older
7. Optimer Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
8. Optimer Pharmaceuticals to Present at the Jefferies 2011 Global Healthcare Conference
9. Optimer Pharmaceuticals Reports First Quarter 2011 Financial Results
10. Optimer Pharmaceuticals Expands Senior Management Team
11. Optimer Pharmaceuticals to Present at May 2011 Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... 22, 2014 Research and Markets ... the "Investment Analysis of the US Medical ... http://photos.prnewswire.com/prnh/20130307/600769 ... medical device sector identifies the key trends and ... investments, and mergers and acquisitions. The ...
(Date:12/22/2014)... and STOCKHOLM , Dec. 22, 2014 ... partner Auxilium Pharmaceuticals, Inc. today announced that the Committee ... European Medicines Agency (EMA) has adopted a positive opinion ... the treatment of adult men with Peyronie,s disease with ... 30 degrees at the start of therapy. ...
(Date:12/22/2014)... 2014  Eiger BioPharmaceuticals Incorporated announced the positive ... in patients with chronic hepatitis delta virus (HDV) ... Institutes of Health (NIH) Clinical Center in ... placebo-controlled, dose ascending study evaluated two doses of ... twice daily for 28 days.  "This proof-of-concept study ...
Breaking Medicine Technology:Investment Analysis of the US Medical Device Sector 2Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 2Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 3Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 4Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 5Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 6Eiger Bio Announces Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib - Results Presented at American Association for the Study of Liver Diseases (AASLD) Meeting 2Eiger Bio Announces Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib - Results Presented at American Association for the Study of Liver Diseases (AASLD) Meeting 3
(Date:12/25/2014)... (HealthDay News) -- The risk of burns from fires ... need to be extra cautious, an expert says. ... significant increase in patients coming in with burns," said ... Volunteer Firefighters Burn Center of Stony Brook University Hospital ... of joy, but if not careful, could quickly turn ...
(Date:12/25/2014)... AngelWeddingDress.com tries its best to translate the experience of ... has introduced its new collection of 2015 prom dresses, ... new prom outfits are guaranteed to contain the perfect ... specially designed for 2015. Anyone who wants to buy ... website before Jan. 26, 2015, the deadline of the ...
(Date:12/25/2014)... Carolina (PRWEB) December 25, 2014 ... Carolina Retirement Community, recently showed their generous spirit ... of the Catawba County Parenting Network- Grandparents Raising ... 10 children gathered around the largest Christmas tree ... open presents purchased by residents of the Abernethy ...
(Date:12/24/2014)... National (PRWEB) December 25, 2014 Over ... back to their local communities. That is 700 smiling ... a single gift. Additionally over $6000 in monetary donations ... help offset some of the expenses they incur through ... years drive were A Child's Haven , Shrine's ...
(Date:12/24/2014)... Risperdal lawsuit ( http://www.risperdallawsuit2014.com/ ) ... currently underway in Pennsylvania’s Philadelphia Court of Common Pleas, ... 2014, court documents indicate that 1,183 claims had been ... developed gynecomastia (male breast growth) and other complications allegedly ... that this represents an increase of more than 100 ...
Breaking Medicine News(10 mins):Health News:Don't Let Burns Mar Your Holidays 2Health News:Angelweddingdress 2015 Prom Dresses Online Now 2Health News:Retirement Community Residents Make Impact During Holiday Season 2Health News:AlignLife Donates Over 700 Toys This Year 2Health News:Risperdal Lawsuits Continue to Climb, as Claims in Pennsylvania Litigation Exceed 1,180 Filings, Bernstein Liebhard LLP Reports 2Health News:Risperdal Lawsuits Continue to Climb, as Claims in Pennsylvania Litigation Exceed 1,180 Filings, Bernstein Liebhard LLP Reports 3Health News:Risperdal Lawsuits Continue to Climb, as Claims in Pennsylvania Litigation Exceed 1,180 Filings, Bernstein Liebhard LLP Reports 4
... TUESDAY, Nov. 8 (HealthDay News) -- Despite concerns that the ... confuse older Americans, a new study finds seniors are able ... The researchers found evidence that seniors -- possibly with the ... as necessary. The findings may ease concerns among some ...
... Reporter , TUESDAY, Nov. 8 (HealthDay News) -- The latest ... might be better than other such scales at spotting people ... Columbia-Suicide Severity Rating Scale (C-SSRS) was developed eight years ago ... The new study, appearing online Nov. 8 in the ...
... What do Moby Dick, the Salem witch trials and alien ... sleep paralysis. Less than 8 percent of the general population ... groups -- students and psychiatric patients -- according to a ... of Pennsylvania. Sleep paralysis is defined as "a discrete period ...
... A team of Virginia Commonwealth University pediatric surgeons today successfully ... Tapia of the Dominican Republic. The complex, 20-hour ... surgery of its kind at the Children,s Hospital of Richmond ... in the VCU Department of Surgery and surgeon-in-chief, the team ...
... , PHILADELPHIA Thomas Jefferson University Hospital is ... to offer the recently-approved U.S. Food and Drug Administration ... BRAF mutation (which occurs in about half of all ... new, potentially life-saving drug. In August, the ...
... , TUESDAY, Nov. 8 (HealthDay News) -- Health care ... hands before and after treating their patients, new research shows. ... of Infection Control and Hospital Epidemiology , this lapse ... settings because some germs can get through latex gloves or ...
Cached Medicine News:Health News:Seniors Choose Medicare Prescription Plans Wisely: Study 2Health News:Suicide Checklist Spots People at Highest Risk 2Health News:Suicide Checklist Spots People at Highest Risk 3Health News:Psychologists chase down sleep demons 2Health News:VCU performs separation surgery on conjoined twins 2Health News:VCU performs separation surgery on conjoined twins 3Health News:Jefferson is first academic medical center to offer FDA-approved BRAF mutation for melanoma patients 2
... Cronin, Inc. is a ... Footwear, Orthopedic Softgoods, and ... Our products are of ... available in the USA ...
... Hinged Ulnar Deviation Splint uses safe, mild ... with ulnar deviation at the MP joints. ... pinch. Radial and ulnar polycentric hinges located ... and extension. Padded, malleable finger rings can ...
... RCAI Dorsal Blocking Splint is constructed of a ... DBS protects the flexor tendons of the hand ... scar tissue development in the later stages of ... dorsally on the hand and positions the wrist ...
Bunell Mini-Modified Safety Finger Pin reduces PIP flexion contractures....
Medicine Products: